ClinicalTrials.gg
Not yet recruitingNCT07224932Updated Oct 8, 2026

Tolerability and Efficacy of CBD Extract for RLS Treatment

A Phase 2 interventional study of BRC-002 and Placecbo in Restless Leg Syndrome, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know

Updated Oct 8, 2026First site in United StatesStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Planned enrollment
39th of 95
60 · median 46
Started
2026
with 1 other
Phase 2
16 of 107
1 open now
Primary completion
2028-03
later than 11 of 12 live
Registered
105th of 107
by date

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 39th largest by planned enrollment of the 95 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 105th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study plans to learn more about the safety and tolerability of high Cannabidiol (CBD) cannabis extract (BRC-002) for use in Idiopathic Restless Legs Syndrome. Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use.

Read the detailed description

This randomized, placebo-controlled clinical trial will evaluate the safety, tolerability, and therapeutic effects of a high-CBD botanical extract in patients with idiopathic RLS. The study will examine changes in symptom severity, sleep quality, mood, and daily functioning to determine whether cannabinoid-based therapy offers a viable alternative or adjunctive treatment for RLS. Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.

03

Conditions studied

  • Restless Leg Syndrome

Keywords

  • Restless Leg Syndrome
  • cannabis
  • BRC-002
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 79 years of age, inclusive.
  2. Willing and able to give .
  3. Idiopathic RLS, meeting all 4 International RLS Study Group diagnostic criteria.
  4. Moderate or severe symptoms, defined as an IRLS score ≥ 15 at screening visit.
  5. RLS medications unchanged for 4 weeks prior to baseline.
  6. Must have a driver or available transportation (including provided Uber vouchers) to drive them to and from study visits and for other transportation needs during the treatment period.
  7. Has a significant other, caregiver, or close acquaintance who knows the subject well and agrees to participate in the subject's neuropsychiatric assessment.
  8. Agrees to not take more than 1 gram per day of acetaminophen.
  9. Whereas applicable, agrees to utilize an effective method of from screening through at least 4 weeks after the completion of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Secondary RLS, such as Parkinson's disease or end-stage renal disease.
  2. Present or past history of another severe sleep disorder.
  3. Currently on night shift work schedule.
  4. History or diagnosis of schizophrenia, bipolar or a psychotic disorder, severe depression, or any mental health illness that would compromise the safety of the participant.
  5. Current suicidal ideation.
  6. Severe cognitive impairment (e.g., Alzheimer's Disease, traumatic brain injury).
  7. Uncontrolled hypertension.
  8. Known or suspected allergy or to cannabinoids or used in the study drug formulation.
  9. Pending legal action or workers compensation.
  10. Cannabis use (THC) detectable at the screening/baseline visits.
  11. History of drug or alcohol dependence.
  12. Use of dopamine blockers, cocaine, or MAO-A inhibitors within 90 days of baseline.
  13. Use of any drugs with known interactions with cannabinoids (e.g., tolcapone, clopidogrel, felbamate, warfarin, barbiturates, benzodiazepines, niacin, nicotinamide, isoniazid, ketoconazole, clobazam, valproate, mTOR inhibitors) within 90 days of baseline.
  14. Unstable medical condition.
  15. laboratory abnormalities.
  16. Moderate or severe hepatic impairment.
  17. Is pregnant, lactating, or has a positive pregnancy test result pre-dose.
  18. Planned elective surgery during study participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Comparator

    Half of the patients will be randomized to receive placebo orally. It is an oral solution of mono-, di-, and triglycerides

    Drug: Placecbo

  • Experimental
    BRC-002

    Half of patients will be randomized to receive oral investigational product. BRC-002 is a non-scheduled high cannabidiol cannabis extract (\<0.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant.

    Drug: BRC-002

Interventions

  • BRC-002 is a non-scheduled cannabidiol (CBD) formulation (\<0.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant. BRC-002 is a high Cannabidiol Botanical extract (100 mg/mL).

    Also known as: Cannabidiol Formulation

  • DrugPlacecbo

    Oral solution of mono-, di-, and triglycerides

06

What researchers measure

Primary outcomes

  1. To examine the safety and tolerability of oral high CBD extract in idiopathic RLS assessed by frequency of adverse events which will be monitored by patient reported adverse events, vital signs, physical exam, and safety labs during study visits.

    Participant reports measures the frequency of adverse events. This will be done with open-ended questions during patient visits and phone calls. Abnormal vital signs (BP, HR, RR) at patient visits measures the frequency of participants with adverse events. BP over 130/80 mmHg indicates worse outcomes. Lower scores indicate worse outcomes. HR ranges from 60 to 100 bpm; Scores outside this range indicates worse outcomes. RR ranges from 12-20 bpm. Scores outside this range indicated worse outcomes. A neurological exam and routine physical exam will be preformed to examine adverse events. Abnormal findings will constitute as an adverse event. Labs (serum CBC w/ diff, serum CMP, urinalysis) will measure frequency of adverse events. Abnormal CBC w/diff, CMP, and urinalysis values will be determined by lab ranges.

    Time frame: Baseline, Visit 3, Visit 4, Visit 5

Secondary outcomes

  1. To examine the effect of BRC-002 on RLS symptoms assessed through changes from baseline in change from baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS)

    The International Restless Legs Syndrome Study Group Rating Scale (IRLS) measures RLS symptoms. Scores range from 0 to 40, with higher scores indicating a worse outcome.

    Time frame: Baseline; Day 20

  2. To examine the effect of BRC-002 on RLS symptoms assessed through changes in sleep quality index (SQI) as measured by the SleepImage Ring

    The SleepImage Recorder ring measures quality of sleep. Scores range from 0 to 100, with higher scores indicating a better outcome.

    Time frame: Baseline; Day 20

  3. To examine the effect of BRC-002 in sleep measured by change in the Epworth Sleepiness Scale (ESS)

    The Epworth Sleepiness Scale (ESS)measures daytime sleepiness. Scores range from 0 to 24, with higher scores indicating a worse outcome.

    Time frame: Baseline; Day 20

  4. To examine the effect of BRC-002 on RLS symptoms assessed through changes in the Fatigue Severity Scale (FSS).

    The Fatigue Severity Scale (FSS) measures fatigue. Scores range from 9 to 63, with higher scores indicating a worse outcome.

    Time frame: Baseline; Day 20

  5. To examine the effect of BRC-002 in cognition measured by change in the Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) measures cognitive impairment. Scores range from 0 to 30, with higher scores indicating a better outcome.

    Time frame: Baseline; Day 20

  6. To examine the effect of BRC-002 in mood measured by change in the Emotional and Behavioral Dyscontrol Short Form.

    The Quality of Life in Neurological Disorders Measurement System (Neurol-QOL) measures mood. Scores range from 0 to 100, with higher scores indicating a better outcome.

    Time frame: Baseline; Day 20

  7. To examine the effect of BRC-002 in suicidality measured by change in the Columbia-Suicide Severity Rating Scale (C-SSRS).

    The C-SSRS measures suicidality in participants. The scores range from 2 through 25; with higher scores indicating worse outcomes.

    Time frame: Baseline; Day 20

  8. To examine the effect of BRC-002 on RLS symptoms assessed through changes in Clinical Global Impression (CGI) Scales

    Clinical Global Impression (CGI) Scales measures improvement in RLS. Scores range from 0 to 7, with higher scores indicating a worse outcome.

    Time frame: Baseline; Day 20

07

Study locations

1 site
  • Colorado Clinical and Translational Sciences Institute (CCTSI) - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Dec 2025 → Nov 2026, primary completion Jan 2026 → Mar 2028 and completion Feb 2026 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Nov 5, 2025
StartEst.
Nov 1, 2026was Dec 2025
Primary completionEst.
Mar 14, 2028was Jan 2026
CompletionEst.
Jun 1, 2028was Feb 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • Colorado Clinical and Translational Sciences Institute (CCTSI) - Anschutz Medical Campus · Aurora, United States
Oct 8, 2026
Start date
Dec 19, 2025→Nov 1, 2026
Oct 8, 2026
Primary completion
Jan 1, 2026→Mar 14, 2028
Oct 8, 2026
Study completion
Feb 25, 2026→Jun 1, 2028
Oct 8, 2026
Secondary outcomes
5 removed
What changed in the outcomes
  • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes from baseline in RLS-6 Severity ScaleTime frame: Baseline; Day 20
  • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in the Pittsburgh Sleep Quality Index (PSQI).Time frame: Baseline; Day 20
  • RemovedTo examine the effect of BRC-002 in psychiatric symptoms measured by change in the Neuropsychiatric Inventory (NPI) assessment.Time frame: Baseline; Day 20
  • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in Patient Reported Outcome Measurement Information System (PROMIS).Time frame: Baseline; Day 20
  • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in Johns Hopkins Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL).Time frame: Baseline; Day 20
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added — first site in United States
    Show site
    • Colorado Clinical and Translational Sciences Institute (CCTSI) - Anschutz Medical Campus · Aurora, United States
    Start date Dec 19, 2025→Nov 1, 2026
    Primary completion Jan 1, 2026→Mar 14, 2028
    Study completion Feb 25, 2026→Jun 1, 2028
    Secondary outcomes 5 removed
    What changed in the outcomes
    • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes from baseline in RLS-6 Severity ScaleTime frame: Baseline; Day 20
    • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in the Pittsburgh Sleep Quality Index (PSQI).Time frame: Baseline; Day 20
    • RemovedTo examine the effect of BRC-002 in psychiatric symptoms measured by change in the Neuropsychiatric Inventory (NPI) assessment.Time frame: Baseline; Day 20
    • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in Patient Reported Outcome Measurement Information System (PROMIS).Time frame: Baseline; Day 20
    • RemovedTo examine the effect of BRC-002 on RLS symptoms assessed through changes in Johns Hopkins Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL).Time frame: Baseline; Day 20
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224932
Collaborators
Biopharmaceutical Research Company
Responsible party
Sponsor
First posted
Nov 5, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 14, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Jacquelyn Bainbridge
Contact
Jacci.Bainbridge@cuanschutz.edu
303-810-4254
Jacquelyn Bainbridge
principal investigator · Skaggs School of Pharmacy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRC-002

Start the discussion